Royal Bank of Canada’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-185,760
| Closed | -$1.85M | – | 7310 |
|
|
2025
Q2 | $1.85M | Buy |
185,760
+184,051
| +10,770% | +$1.48M | ﹤0.01% | 3372 |
|
|
2025
Q1 | $10K | Sell |
1,709
-1,698
| -50% | -$12.5K | ﹤0.01% | 6155 |
|
|
2024
Q4 | $26K | Buy |
3,407
+647
| +23% | +$5.56K | ﹤0.01% | 6000 |
|
|
2024
Q3 | $28K | Buy |
2,760
+318
| +13% | +$4.85K | ﹤0.01% | 5976 |
|
|
2024
Q2 | $36K | Buy |
2,442
+1,045
| +75% | +$15K | ﹤0.01% | 5800 |
|
|
2024
Q1 | $19K | Sell |
1,397
-5,552
| -80% | -$60.5K | ﹤0.01% | 5943 |
|
|
2023
Q4 | $76K | Buy |
6,949
+2,788
| +67% | +$27.6K | ﹤0.01% | 5771 |
|
|
2023
Q3 | $46K | Buy |
4,161
+1,575
| +61% | +$20.1K | ﹤0.01% | 5827 |
|
|
2023
Q2 | $34K | Buy |
2,586
+1,255
| +94% | +$17.9K | ﹤0.01% | 5957 |
|
|
2023
Q1 | $18K | Sell |
1,331
-1,369
| -51% | -$24.5K | ﹤0.01% | 6063 |
|
|
2022
Q4 | $53K | Buy |
2,700
+2,395
| +785% | +$46.8K | ﹤0.01% | 5838 |
|
|
2022
Q3 | $5K | Buy |
305
+136
| +80% | +$3.13K | ﹤0.01% | 6732 |
|
|
2022
Q2 | $4K | Sell |
169
-1,077
| -86% | -$25.6K | ﹤0.01% | 6725 |
|
|
2022
Q1 | $40K | Sell |
1,246
-2,166
| -63% | -$78.7K | ﹤0.01% | 6238 |
|
|
2021
Q4 | $158K | Buy |
3,412
+1,248
| +58% | +$41.5K | ﹤0.01% | 5568 |
|
|
2021
Q3 | $59K | Sell |
2,164
-310
| -13% | -$8.1K | ﹤0.01% | 6066 |
|
|
2021
Q2 | $63K | Buy |
2,474
+742
| +43% | +$17.7K | ﹤0.01% | 5879 |
|
|
2021
Q1 | $59K | Buy |
1,732
+1,458
| +532% | +$52.7K | ﹤0.01% | 5786 |
|
|
2020
Q4 | $9K | Buy |
+274
| New | +$7.25K | ﹤0.01% | 6428 |
|
Other funds holding ITOS
Royal Bank of Canada's ITOS Position: Q3 2025 in Review
Royal Bank of Canada sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 185,760 shares — an estimated $1.85M sold.
Royal Bank of Canada first reported a position in ITOS in Q4 2020 and held it in 19 quarters. The position peaked at $1.85M in Q2 2025. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- Royal Bank of Canada reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- Royal Bank of Canada sold 185,760 iTeos Therapeutics shares in Q3 2025, an estimated $1.85M.
- Royal Bank of Canada first reported a position in iTeos Therapeutics in Q4 2020 and held it in 19 quarters.
- Royal Bank of Canada's iTeos Therapeutics position peaked at $1.85M in Q2 2025.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on Royal Bank of Canada's 13F filing for Q3 2025, filed 14 Nov 2025.